Exactly one human oxytocin product carries FDA approval: oxytocin injection, USP, a sterile solution of synthetic oxytocin at 10 USP units per mL, and its approved indications are entirely obstetric. The distance between that approval and the drug's public reputation is the whole story, because nothing sold for bonding, mood, intimacy, or wellbeing sits anywhere inside it.
FDA-approved oxytocin means one injectable obstetric drug, oxytocin injection USP at 10 USP units per mL, indicated only for antepartum initiation or improvement of uterine contractions and for postpartum uterine contraction and control of bleeding.
Pitocin is the brand name under which oxytocin injection, USP, is marketed in the United States, and the New Drug Application currently sits with Par Health USA, LLC, the sterile injectables business formerly known as Endo's Par Sterile Products. Ownership of an application this old moves around, so the holder of record on any given day is a matter for FDA's Drugs@FDA database rather than memory.
The Pitocin New Drug Application is held by Par Health USA, LLC, and covers synthetic oxytocin supplied as a sterile aqueous solution at 10 USP units per mL, with potency expressed in USP units rather than milligrams.
The antepartum indication sets a standard rather than a closed list of qualifying diagnoses: oxytocin may be used to start or improve uterine contractions where early vaginal delivery is judged suitable for fetal or maternal reasons. That phrasing leaves the case with the prescriber, which is why the boxed statement about elective induction carries so much weight here. A medical reason making early delivery preferable is the hinge the entire antepartum indication turns on.
The approved antepartum indication requires a medical reason making early vaginal delivery preferable, and the labeling restricts induction and augmentation to the intravenous route under continuous observation by trained personnel in a hospital, with a physician qualified to manage complications immediately available.
Two things, stated plainly: producing uterine contractions during the third stage of labor, and controlling postpartum bleeding or hemorrhage. This is the narrower and less contested half of the approval, and it is the reason oxytocin injection sits on the World Health Organization's Model List of Essential Medicines, since postpartum hemorrhage remains a leading cause of maternal death worldwide and a uterus clamping down on its own bleeding vessels is the first line of defense.
| Criteria | Antepartum use | Postpartum use |
|---|---|---|
| Mechanical goal | Rhythmic contractions a fetus can tolerate | Sustained tonic clamp |
| Labeled route | Intravenous infusion, diluted | 10 units intramuscularly after placental delivery, or infusion |
| Labeled concentration | 10 units in 1000 mL, titrated in milliunits per minute | 10 to 40 units in 1000 mL of a nonhydrating diluent |
| Titration precision | Fine; fetal oxygenation depends on relaxation between contractions | Coarser; no fetus in the circuit |
| Water intoxication warning | Applies to prolonged high-rate infusion | Applies unchanged after delivery |
The approved postpartum indications are limited to producing uterine contractions during the third stage of labor and controlling postpartum bleeding, with the label supporting 10 units intramuscularly after delivery of the placenta or an infusion of 10 to 40 units in 1000 mL of a nonhydrating diluent.
The boxed warning is misread in both directions. It states that the product is not indicated for elective induction of labor, defines elective induction as initiation of labor in a pregnant individual with no medical indication for it, and gives its reason plainly: the available data were inadequate to evaluate the benefit-to-risk considerations. That is a statement about evidence, not a finding of danger.
The boxed warning states that oxytocin is not indicated for elective induction of labor because the available data were inadequate to evaluate benefit-to-risk considerations, which constrains what the label may claim rather than prohibiting a licensed prescriber's off-label clinical judgment.
Generic oxytocin injection reaches the market through the Abbreviated New Drug Application pathway, referencing Pitocin as the reference listed drug and matching it on active ingredient, strength, dosage form, and route. A generic inherits the reference product's labeling, so it inherits the same two obstetric indication groups and the same boxed warning, with no additional latitude in what may be claimed for it. Supply is the part with operational teeth: injectable oxytocin has appeared on drug shortage lists, and a first-line uterotonic with no approved substitute leaves only second-line agents when it tightens.
| Criteria | Pitocin (reference listed drug) | ANDA generic |
|---|---|---|
| Approval pathway | New Drug Application | Abbreviated New Drug Application |
| Strength and form | 10 USP units per mL, sterile injection | Identical |
| Labeled indications | Two obstetric groups | Inherited, unchanged |
| Boxed warning | Elective induction not indicated | Inherited, unchanged |
A generic oxytocin injection approved through an Abbreviated New Drug Application carries labeling matched to Pitocin apart from permitted differences such as the manufacturer's name, including both obstetric indication groups and the boxed warning, so no US oxytocin product holds a broader approved use than the brand.
There was one, and its story is routinely misrepresented. Syntocinon nasal spray was approved in the United States for a single narrow purpose, aiding initial milk ejection before breastfeeding or pumping, and nothing in that approval spoke to mood, bonding, trust, anxiety, or intimacy. It was discontinued, is no longer marketed here, and no intranasal oxytocin product is FDA-approved and available in the United States today.
The only intranasal oxytocin ever approved in the United States was Syntocinon nasal spray, indicated solely to aid initial milk letdown before breastfeeding, and it has been discontinued, leaving no FDA-approved intranasal oxytocin product on the US market.
Almost everything the public associates with the word sits outside the approval: autism spectrum disorder, social anxiety, post-traumatic stress disorder, depression, schizophrenia, bonding, libido, pain, weight, wound healing, general wellbeing. The absence is not a paperwork lag. The behavioral hypothesis was tested at scale, and the largest and best-designed test cut against it.
No FDA-approved oxytocin product exists for autism, social anxiety, PTSD, depression, schizophrenia, bonding, libido, pain, weight, or wound healing, and the 2021 SOARS-B trial found no significant benefit of intranasal oxytocin on social or cognitive outcomes over 24 weeks.
One form, one concentration: a sterile solution for injection at 10 USP units per mL. That is the entire approved human dosage-form landscape in the United States, with no approved oral, sublingual, buccal, transdermal, or nasal product; oxytocin is a nine-amino-acid peptide degraded in the gastrointestinal tract, so swallowing it does not deliver a systemic dose in any meaningful sense. The route restriction inside the injection is substantive rather than bureaucratic, because the same molecule that safely establishes labor at 2 milliunits per minute can drive tetanic contraction, fetal compromise, and uterine rupture if the rate runs away, which is why institutional safety practice classifies it as a high-alert medication.
The only approved human oxytocin dosage form in the United States is a sterile injection at 10 USP units per mL, and for induction or stimulation of labor the label permits intravenous infusion by the drip method as the only acceptable form of parenteral administration.
No. Oxytocin injection is genuinely FDA-approved for veterinary use in cattle, horses, swine, sheep, dogs, and cats, for obstetric purposes such as uterine inertia and retained placenta and for milk letdown in dairy animals, but that approval comes from a separate center reviewing a separate application against a separate standard. The stakes are not hypothetical: veterinary oxytocin is inexpensive, moves through agricultural supply channels, and meets far less dispensing friction than a hospital pharmacy product, which makes it an occasional entry point into gray-market human use.
| Criteria | Veterinary approval | Human approval |
|---|---|---|
| Reviewing center | Center for Veterinary Medicine | Center for Drug Evaluation and Research |
| Population evaluated | Cattle, horses, swine, sheep, dogs, cats | Humans |
| Additional standard applied | Residues in milk and meat from food animals | Human safety and efficacy |
| Labeling content | No human indication, no human dosing | Obstetric indications, milliunit dosing |
FDA approval of oxytocin injection for animals is granted by the Center for Veterinary Medicine against a separate standard concerned with the target species and with residues in milk and meat, and its labeling carries no human indication and no human dosing, so it says nothing about the human regulatory status of the molecule.
Educational use only. This article describes what the published scientific and clinical literature reports about Oxytocin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
